Generex wouldn’t need anywhere near the developments costs of Moderna or any Mrna company. Antigen Express (NGIO) began development of their Ii-Key peptide vaccines for infectious diseases long ago. Today they are building upon that prior work. Also, developing and later selling peptide vaccines is far less costly as is manufacturing.